Oncodesign Precision Medicine (XPAR:ALOPM) Cash-to-Debt : 0.56 (As of Jun. 2022)

View and export this data going back to 2022. Start your Free Trial

What is Oncodesign Precision Medicine Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Oncodesign Precision Medicine's cash to debt ratio for the quarter that ended in Jun. 2022 was 0.56.

If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Oncodesign Precision Medicine couldn't pay off its debt using the cash in hand for the quarter that ended in Jun. 2022.

The historical rank and industry rank for Oncodesign Precision Medicine's Cash-to-Debt or its related term are showing as below:

XPAR:ALOPM's Cash-to-Debt is not ranked ^*
in the Biotechnology industry.
Industry Median: 6.51
* Ranked among companies with meaningful Cash-to-Debt only.

Oncodesign Precision Medicine Cash-to-Debt Historical Data

The historical data trend for Oncodesign Precision Medicine's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Oncodesign Precision Medicine Cash-to-Debt Chart

Oncodesign Precision Medicine Annual Data

Trend

Dec20

Dec21

Cash-to-Debt

2.69

1.69

Oncodesign Precision Medicine Semi-Annual Data
	Dec20	Dec21	Jun22
Cash-to-Debt	2.69	1.69	0.56

Competitive Comparison of Oncodesign Precision Medicine's Cash-to-Debt

For the Biotechnology subindustry, Oncodesign Precision Medicine's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Oncodesign Precision Medicine's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oncodesign Precision Medicine's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Oncodesign Precision Medicine's Cash-to-Debt falls into.

Oncodesign Precision Medicine Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Oncodesign Precision Medicine's Cash to Debt Ratio for the fiscal year that ended in Dec. 2021 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	4.921	/	(0	+	2.907)
	=	1.69

Oncodesign Precision Medicine's Cash to Debt Ratio for the quarter that ended in Jun. 2022 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	1.501	/	(0	+	2.684)
	=	0.56

Oncodesign Precision Medicine (XPAR:ALOPM) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Oncodesign Precision Medicine Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Oncodesign Precision Medicine's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Oncodesign Precision Medicine (XPAR:ALOPM) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oncodesign Precision Medicine SA (XPAR:ALOPM) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

18 rue Jean Mazen, Dijon, FRA, 21000

Website

https://www.opm.oncodesign.com

Oncodesign Precision Medicine SA is a biopharmaceutical company specialised in precision medicine. Its mission is to provide patients with effective diagnostic and therapeutic solutions for resistant and metastatic cancers.

Oncodesign Precision Medicine (XPAR:ALOPM) Headlines

No Headlines